Generic Entry, Reformulations and Promotion of SSRIs in the US
The introduction of new product formulations appears to be a common strategy for attempting to extend market exclusivity for medications facing impending generic entry. Manufacturers who introduced a reformulation before generic entry shifted most promotion dollars from the original brand to the reformulation long before generic entry, and in some cases manufacturers appeared to target a particular promotion type for a given indication. Given the significant impact that pharmaceutical promotion has on demand for prescription drugs in the US, these findings have important implications for prescription drug spending and public health. </AbstractSection> Copyright Adis Data Information BV 2008
Year of publication: |
2008
|
---|---|
Authors: | Huskamp, Haiden ; Donohue, Julie ; Koss, Catherine ; Berndt, Ernst ; Frank, Richard |
Published in: |
PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 26.2008, 7, p. 603-616
|
Publisher: |
Springer |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
Demand Effects of Recent Changes in Prescription Drug Promotion
Rosenthal, Meredith, (2003)
-
The impact of a three-tier formulary on demand response for prescription drugs
Huskamp, Haiden A., (2005)
-
The effect of FDA advisories on branded pharmaceutical firms' valuations and promotion efforts
Conti, Rena M., (2011)
- More ...